Adaptive Biotechnologies Corp (ADPT) — SEC Financial Statements & Analysis

Adaptive Biotechnologies Corp (ADPT) is a biological products, (no diagnostic substances) company, incorporated in WA. Adaptive Biotechnologies Corp trades on Nasdaq as: ADPT. Adaptive Biotechnologies Corp (ADPT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04. Based on that filing, Adaptive Biotechnologies Corp carries a market cap of $3.43B, a P/E ratio of -53.55x, a P/B ratio of 22.76x, a P/S ratio of 11.13x, an enterprise value of $3.26B, and an EV/EBITDA multiple of -141.54x. On profitability, it posts a gross margin of 75.57%, an operating margin of -12.16%, a net margin of -20.78%, a Return on Equity (ROE) of -38.78%, a Return on Assets (ROA) of -11.26%, and a Return on Invested Capital (ROIC) of -16.68%. Per share, it reports EPS of $-0.40, diluted EPS of $-0.40, free cash flow per share of $-0.15, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 50.13% year-over-year, net income growth of -47.15% year-over-year, and EPS growth of -49.72% year-over-year. On the balance sheet, it maintains a current ratio of 4.79x, a quick ratio of 4.49x, working capital of $332.85M, a debt-to-equity ratio of 3.25x, a debt ratio of 0.76, an interest coverage ratio of -3.26x, free cash flow of $-24.03M (TTM), and net debt of $-169.87M. Figures sourced from SEC EDGAR.

Market Cap

$3.43B

P/E TTM

-53.55x

EPS TTM

$-0.40

P/B TTM

22.76x

ROE TTM

-38.78%

ROA TTM

-11.26%

Debt To Equity

3.25x

Free Cash Flow TTM

$-24.03M

Net Revenue TTM Growth 1Y

50.13%

Data as of 2026-06-30 · Source: SEC EDGAR